glp-1 obesity drug news today september 15 2025 anti-obesity drugs lead to substantial weight loss in the “real world” The first of three of
Description
What happens if you stop taking GLP-1 medications suddenly
Although AOM liraglutide (Saxenda) has been approved for treatment of obesity in adolescents since late 2020 ( 5 ), the approval of AOM semaglutide (Wegovy) in December 2022 for treatment of obesity for adolescents prompted new excitement ( 6 )
Since in all of the above studies the terminologies NAFLD/NASH were applied, these definitions will be used in this review
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
They also play a role in helping the muscle fibers generate force by improving the way key proteins interact
There is no need to change dosages in older people based solely on age
